A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Fiche publication
Date publication
janvier 2021
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Dr BEN ABDELGHANI Meher, Pr PETIT Thierry, Pr PIVOT Xavier, Dr SCHOTT Roland, Dr DEMARCHI Martin, Dr COLIAT Pierre
Tous les auteurs :
Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X
Lien Pubmed
Résumé
This first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sourced and US-sourced bevacizumab (NCT03390673).
Référence
PLoS One. 2021 ;16(9):e0248222